title: Impact of the short-term, intense exercise on postprandial glycemia in type 2 diabetic patients treated with gliclazide.
abstract: BACKGROUND
  Physical activity is crucial for treatment of diabetes. However, intensive exercise brings the risk for metabolic decompensation; therefore, predicting its effect on glycemia is of great importance.
  
  
  METHODS
  Fourteen type 2 diabetic patients (47.9+/-1.6 years; mean+/-S.E.M.), treated with gliclazide, and 14 healthy controls (45.1+/-1.0 years) were subjected to standard graded submaximal (90% HR(max)) exercise treadmill testing for 2 h after standardized breakfast. Blood glucose, lactate, insulin, and proinsulin concentrations were measured on fasting and during the periexercise period up to 120 min after the effort. Glucagon, growth hormone, cortisol, and catecholamines were determined up to 60 min of the recovery period.
  
  
  RESULTS
  After exercise, glycemia decreased from the preexercise value of 11.3+/-1.4 to 8.0+/-1.1 mmol/l at 120 min (P<.001) in the diabetic group, while in controls, it did not change significantly. Shift in glycemia during and after exercise in the diabetic group was dependent on preexercise glycemia, according to the quadratic polynomial regression model, whereas a simple negative correlation between these indices was found in the control group. Insulinemia tended to decrease from the midexercise maximum of 488+/-116 to 261+/-71 pmol/l at the 120th min in diabetic patients. Neither hypoglycemia nor deficit in response of counterregulatory hormones was observed.
  
  
  CONCLUSIONS
  In the type 2 diabetic patients treated with gliclazide, short-term, intensive, submaximal exercise, performed 2 h after a meal, causes reduction of hyperglycemia during the recovery period. Preexercise glycemia was found to be a primary predictor of the shift in glycemia under the exercise, according to the polynomial regression model.
authors.affiliation: Department of Internal Nursing, Medical University of Silesia, 40-635 Katowice, Poland. jszewieczek@slam.katowice.pl
authors.forename: Jan
authors.initials: J
authors.lastname: Szewieczek
authors.forename: Jan
authors.initials: J
authors.lastname: Dulawa
authors.forename: Dorota
authors.initials: D
authors.lastname: Strzałkowska
authors.forename: Beata
authors.initials: B
authors.lastname: Hornik
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Kawecki
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D004837:Epinephrine / Q000097:blood; D015444:Exercise / Q000502:physiology*; D005080:Exercise Test; D005907:Gliclazide / Q000627:therapeutic use*; D005934:Glucagon / Q000097:blood; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000097:blood; D007773:Lactates / Q000097:blood; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000097:blood; D019518:Postprandial Period / Q000502:physiology*; D013997:Time Factors
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D007773:Lactates; D013006:Growth Hormone; D005934:Glucagon; D005907:Gliclazide; D006854:Hydrocortisone; D009638:Norepinephrine; D004837:Epinephrine